Expert Interview
A discussion on the potential of Lannett's (LCI) generic chemo agent temozolomide capsules to gain a portion of Merck's (MRK) market share for temodar in a certain type of brain tumor
Ticker(s): MRK, LCIAn expert with significant experience treating patients with this type of brain tumor who has deep knowledge of the labels, data, and profiles for temodar and temozolomide.
Can you describe your experience treating patients with this type of brain tumor and your knowledge of the labels, data, and profiles of temodar and temozolomide?
Added By: pjloriaAre there any significant differences in the labels, data, and profiles for temodar and the generic capsul temozolomide?
Added By: pjloriaHow many patients would you estimate are in the market for this particular type of brain tumor?
Added By: pjloriaWhat are the pricing differences for temodar and temozolomide?
Added By: pjloriaWhat percentage of patients do you think will use temozolomide over temodar going forward?
Added By: pjloriaWhy would a patient choose temodar over temozolomide?
Added By: pjloriaIs there potential for patients who are currently taking temodar to switch to temozolomide?
Added By: pjloriaWhat obstacles will Lannett face in marketing temozolomide?
Added By: pjloriaAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
- Lannett Receives FDA Approval For Temozolomide Capsules LCI Occurred On: Feb 11, 2016
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
